Praxis Precision Medicines (PRAX) Stock Forecast, Price Target & Predictions
PRAX Stock Forecast
Praxis Precision Medicines stock forecast is as follows: an average price target of $145.83 (represents a 78.45% upside from PRAX’s last price of $81.72) and a rating consensus of 'Buy', based on 7 wall street analysts offering a 1-year stock forecast.
PRAX Price Target
The average price target for Praxis Precision Medicines (PRAX) is $145.83 based on 1-year price targets from 7 Wall Street analysts in the past 3 months, with a price target range of $170.00 to $120.00. This represents a potential 78.45% upside from PRAX's last price of $81.72.
PRAX Analyst Ratings
According to 7 Wall Street analysts, Praxis Precision Medicines's rating consensus is 'Buy'. The analyst rating breakdown for PRAX stock is 0 'Strong Buy' (0.00%), 7 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Praxis Precision Medicines Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Sep 04, 2024 | Douglas Tsao | H.C. Wainwright | $120.00 | $58.18 | 106.26% | 46.84% |
| Sep 04, 2024 | Ami Fadia | Needham | $151.00 | $58.18 | 159.54% | 84.78% |
| Sep 03, 2024 | Francois Brisebois | Oppenheimer | $143.00 | $55.38 | 158.22% | 74.99% |
| Sep 03, 2024 | Joon Lee | Truist Financial | $150.00 | $53.95 | 178.01% | 83.55% |
| Aug 14, 2024 | Ami Fadia | Needham | $145.00 | $51.26 | 182.87% | 77.44% |
| Aug 14, 2024 | Yatin Suneja | Guggenheim | $170.00 | $52.24 | 225.42% | 108.03% |
| Aug 05, 2024 | Francois Brisebois | Oppenheimer | $134.00 | $53.52 | 150.37% | 63.97% |
| May 28, 2024 | Kambiz Yazdi | Jefferies | $141.00 | $44.08 | 219.87% | 72.54% |
| Mar 26, 2024 | Kambiz Yazdi | Jefferies | $128.00 | $62.18 | 105.85% | 56.63% |
The latest Praxis Precision Medicines stock forecast, released on Sep 04, 2024 by Douglas Tsao from H.C. Wainwright, set a price target of $120.00, which represents a 106.26% increase from the stock price at the time of the forecast ($58.18), and a 46.84% increase from PRAX last price ($81.72).
Praxis Precision Medicines Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 6 | 9 |
| Avg Price Target | - | $146.50 | $142.44 |
| Last Closing Price | $81.72 | $81.72 | $81.72 |
| Upside/Downside | -100.00% | 79.27% | 74.30% |
In the current month, the average price target of Praxis Precision Medicines stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Praxis Precision Medicines's last price of $81.72. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Oct 14, 2024 | Oppenheimer | Outperform | Outperform | Hold |
| Sep 24, 2024 | Cowen & Co. | Buy | Buy | Hold |
| Sep 04, 2024 | Piper Sandler | Underperform | Underperform | Hold |
| Sep 04, 2024 | Wedbush | Buy | Buy | Hold |
| Sep 04, 2024 | Needham | Buy | Buy | Hold |
| Sep 04, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Sep 03, 2024 | Oppenheimer | Outperform | Outperform | Hold |
| Sep 03, 2024 | Cowen & Co. | Buy | Buy | Hold |
| Aug 21, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| Aug 14, 2024 | Guggenheim | Buy | Buy | Hold |
Praxis Precision Medicines's last stock rating was published by Oppenheimer on Oct 14, 2024. The company gave PRAX a "Outperform" rating, the same as its previous rate.
Praxis Precision Medicines Financial Forecast
Praxis Precision Medicines Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | $44.09M | $18.00M | $5.00M | $302.00K | $258.67K | $258.67K | $258.67K | $258.67K | $405.56K | $328.56K | $931.22K | $1.88M | $300.00K |
| High Forecast | $64.21M | $26.21M | $7.28M | $439.81K | $376.70K | $376.70K | $376.70K | $373.07K | $596.40K | $478.48K | $931.33K | $1.88M | $436.89K |
| Low Forecast | $25.69M | $10.49M | $2.91M | $175.92K | $150.68K | $150.68K | $150.68K | $149.23K | $238.56K | $191.39K | $931.11K | $1.88M | $174.76K |
| # Analysts | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 5 | 7 | 3 | 1 | 1 | 3 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - |
Praxis Precision Medicines's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. PRAX's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
Praxis Precision Medicines EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 5 | 7 | 3 | 1 | 1 | 3 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | $26.46M | $10.80M | $3.00M | $181.20K | $155.20K | $155.20K | $155.20K | $155.20K | $243.33K | $197.13K | $558.73K | $1.13M | $180.00K |
| High Forecast | $38.53M | $15.73M | $4.37M | $263.88K | $226.02K | $226.02K | $226.02K | $223.84K | $357.84K | $287.09K | $558.80K | $1.13M | $262.13K |
| Low Forecast | $15.41M | $6.29M | $1.75M | $105.55K | $90.41K | $90.41K | $90.41K | $89.54K | $143.14K | $114.83K | $558.67K | $1.13M | $104.85K |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - |
undefined analysts predict PRAX's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Praxis Precision Medicines's previous annual EBITDA (undefined) of $NaN.
Praxis Precision Medicines Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 5 | 7 | 3 | 1 | 1 | 3 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | $-34.37M | $-53.07M | $-59.30M | $-58.16M | $-59.92M | $-57.65M | $-56.46M | $-54.20M | $-52.71M | $-37.56M | $-43.72M | $-39.33M | $-57.63M |
| High Forecast | $-15.72M | $-24.27M | $-27.12M | $-26.60M | $-27.40M | $-26.36M | $-25.82M | $-41.72M | $-45.47M | $-17.18M | $-19.99M | $-17.99M | $-52.14M |
| Low Forecast | $-54.76M | $-84.54M | $-94.47M | $-92.67M | $-95.46M | $-91.85M | $-89.96M | $-57.90M | $-56.60M | $-59.84M | $-69.65M | $-62.67M | $-65.68M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - |
Praxis Precision Medicines's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. PRAX's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Praxis Precision Medicines SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 5 | 7 | 3 | 1 | 1 | 3 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | $186.83M | $76.27M | $21.19M | $1.28M | $1.10M | $1.10M | $1.10M | $1.10M | $1.72M | $1.39M | $3.95M | $7.98M | $1.27M |
| High Forecast | $272.09M | $111.07M | $30.85M | $1.86M | $1.60M | $1.60M | $1.60M | $1.58M | $2.53M | $2.03M | $3.95M | $7.98M | $1.85M |
| Low Forecast | $108.84M | $44.43M | $12.34M | $745.41K | $638.46K | $638.46K | $638.46K | $632.32K | $1.01M | $810.96K | $3.95M | $7.98M | $740.48K |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - |
Praxis Precision Medicines's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to PRAX last annual SG&A of $NaN (undefined).
Praxis Precision Medicines EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 5 | 7 | 3 | 1 | 1 | 3 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | $-1.82 | $-2.81 | $-3.14 | $-3.08 | $-3.17 | $-3.05 | $-2.99 | $-2.87 | $-2.79 | $-1.99 | $-2.31 | $-2.08 | $-3.05 |
| High Forecast | $-0.83 | $-1.28 | $-1.44 | $-1.41 | $-1.45 | $-1.40 | $-1.37 | $-2.21 | $-2.41 | $-0.91 | $-1.06 | $-0.95 | $-2.76 |
| Low Forecast | $-2.90 | $-4.48 | $-5.00 | $-4.91 | $-5.06 | $-4.86 | $-4.76 | $-3.07 | $-3.00 | $-3.17 | $-3.69 | $-3.32 | $-3.48 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - |
According to undefined Wall Street analysts, Praxis Precision Medicines's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to PRAX previous annual EPS of $NaN (undefined).
Praxis Precision Medicines Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| PMVP | PMV Pharmaceuticals | $1.65 | $18.00 | 990.91% | Buy |
| IMRX | Immuneering | $1.71 | $17.50 | 923.39% | Buy |
| ANTX | AN2 Therapeutics | $1.01 | $8.75 | 766.34% | Buy |
| PEPG | PepGen | $4.55 | $29.50 | 548.35% | Buy |
| MOLN | Molecular Partners | $5.51 | $29.00 | 426.32% | Buy |
| ANEB | Anebulo Pharmaceuticals | $1.55 | $6.00 | 287.10% | Buy |
| ELYM | Eliem Therapeutics | $5.11 | $13.00 | 154.40% | Buy |
| MLYS | Mineralys Therapeutics | $12.45 | $30.00 | 140.96% | Buy |
| STOK | Stoke Therapeutics | $13.90 | $30.60 | 120.14% | Buy |
| CGEM | Cullinan Oncology | $15.79 | $31.50 | 99.49% | Buy |
| PHVS | Pharvaris | $20.04 | $39.67 | 97.95% | Buy |
| PRAX | Praxis Precision Medicines | $81.72 | $145.83 | 78.45% | Buy |
| ELVN | Enliven Therapeutics | $25.80 | $35.50 | 37.60% | Buy |
| EWTX | Edgewise Therapeutics | $33.26 | $45.00 | 35.30% | Buy |
| DYN | Dyne Therapeutics | $34.13 | $43.88 | 28.57% | Buy |
| CRNX | Crinetics Pharmaceuticals | $58.92 | $70.14 | 19.04% | Buy |
| RVMD | Revolution Medicines, Inc. Warrant | $58.13 | $60.63 | 4.30% | Buy |